1. Home
  2. CNTX vs CRT Comparison

CNTX vs CRT Comparison

Compare CNTX & CRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • CRT
  • Stock Information
  • Founded
  • CNTX 2015
  • CRT 1991
  • Country
  • CNTX United States
  • CRT United States
  • Employees
  • CNTX N/A
  • CRT N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • CRT Oil & Gas Production
  • Sector
  • CNTX Health Care
  • CRT Energy
  • Exchange
  • CNTX Nasdaq
  • CRT Nasdaq
  • Market Cap
  • CNTX 78.0M
  • CRT 65.1M
  • IPO Year
  • CNTX 2021
  • CRT 1992
  • Fundamental
  • Price
  • CNTX $0.65
  • CRT $9.85
  • Analyst Decision
  • CNTX Strong Buy
  • CRT
  • Analyst Count
  • CNTX 5
  • CRT 0
  • Target Price
  • CNTX $5.50
  • CRT N/A
  • AVG Volume (30 Days)
  • CNTX 324.1K
  • CRT 24.7K
  • Earning Date
  • CNTX 08-06-2025
  • CRT 01-01-0001
  • Dividend Yield
  • CNTX N/A
  • CRT 9.01%
  • EPS Growth
  • CNTX N/A
  • CRT N/A
  • EPS
  • CNTX N/A
  • CRT 0.99
  • Revenue
  • CNTX N/A
  • CRT $6,834,116.00
  • Revenue This Year
  • CNTX N/A
  • CRT N/A
  • Revenue Next Year
  • CNTX N/A
  • CRT N/A
  • P/E Ratio
  • CNTX N/A
  • CRT $9.89
  • Revenue Growth
  • CNTX N/A
  • CRT N/A
  • 52 Week Low
  • CNTX $0.49
  • CRT $8.88
  • 52 Week High
  • CNTX $2.75
  • CRT $13.31
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 50.76
  • CRT 48.08
  • Support Level
  • CNTX $0.62
  • CRT $9.74
  • Resistance Level
  • CNTX $0.70
  • CRT $9.88
  • Average True Range (ATR)
  • CNTX 0.05
  • CRT 0.17
  • MACD
  • CNTX 0.01
  • CRT 0.02
  • Stochastic Oscillator
  • CNTX 56.44
  • CRT 31.94

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About CRT Cross Timbers Royalty Trust

Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.

Share on Social Networks: